GlassScriptPhysician profile
Naveed Chowhan
NPI 1164440962
$16,724.00
in general payments reported to CMS, 2019-2025
68 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,045 · 2020: $2,082 · 2021: $2,049 · 2022: $7,592 · 2023: $641 · 2024: $130 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $3,382.99 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,889.22 | 2019-2023 | |
| Puma Biotechnology, INC. | $1,319.65 | 2019-2023 | |
| Pfizer INC. | $732.88 | 2019-2024 | |
| Amgen INC. | $660.19 | 2020-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $654.64 | 2019-2024 | Opdualag |
| Merck Sharp & Dohme LLC | $602.51 | 2019-2023 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $555.76 | 2019-2023 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals LP | $551.23 | 2019-2024 | |
| Janssen Biotech, INC. | $461.06 | 2019-2023 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $417.63 | 2019-2023 | Padcev |
| Incyte Corporation | $380.78 | 2021-2023 | Jakafi |
| Eisai INC. | $345.06 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $319.63 | 2019-2023 | Ninlaro |
| Coherus Oncology, INC. | $290.98 | 2020-2023 |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Chowhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.